Celularity Inc (CELU): Nasdaq/NYSE listing notice — Celularity receives Nasdaq delisting notice for bid price below $1.00

Celularity Inc

Closing bid price of Class A common stock (CELU) below $1.00 for 30 consecutive business days.
Company has 180 calendar days, until September 11, 2023, to regain compliance by closing at $1.00+ for 10 consecutive days.
If not compliant by deadline, Celularity may be eligible for an additional 180-day grace period if it meets other Nasdaq requirements.
Stock continues to trade on Nasdaq Capital Market under CELU; company evaluating options to cure deficiency.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Celularity Inc received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1), 5810(c)(3)(A)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5450(a)(1), 5810(c)(3)(A)

Exact text from the filing

March 14, 2023, Celularity Inc. (the “Company”) received notice from the Listing Qualifications department of the Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that the Company no longer complies with the minimum bid price requirement for continued listing on the Nasdaq Capital Market under Nasdaq Listing Rule 5450(a)(1) because the closing bid price for the Company’s Class A common stock has fallen below $1.00 per share for the last 30 consecutive business days. Nasdaq’s notice has no immediate effect on the listing of the Company’s common stock, which continues to trade on the Nas

View on SEC.gov

20 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

Celularity Inc filing history →

Source: SEC EDGAR

accession 0000950170-23-008662

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.